NCT02568332View on ClinicalTrials.gov

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

January 26, 2017

Study Completion Date

October 31, 2017

Conditions
Hepatitis C Infection
Interventions
BIOLOGICAL

AdCh3NSmut1

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

MVA-NSmut

Genetic vaccine against Hepatitis C virus infection

Trial Locations (2)

9007

Kantonsspital St. Gallen, Sankt Gallen

Dublin 8

St James's Hospital, Dublin

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

ReiThera Srl

INDUSTRY

collaborator

Cantonal Hospital of St. Gallen

OTHER

collaborator

St. James's Hospital, Ireland

OTHER

lead

University of Oxford

OTHER

NCT02568332 - A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals | Biotech Hunter | Biotech Hunter